The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: A systematic literature review

Researchers compared the clinical and economic outcomes associated with the administration of chimeric antigen receptor (CAR)-T cell therapies in both the inpatient and outpatient setting for patients with hematological cancer. Existing evidence was summarized and the hypothesis that outpatient administration of CAR-T therapies yields comparable clinical effectiveness as inpatient treatment while offering significant cost reduction and lower humanistic burden was tested.